Ingrid Kromann

3.0k total citations
23 papers, 1.4k citations indexed

About

Ingrid Kromann is a scholar working on Infectious Diseases, Immunology and Molecular Biology. According to data from OpenAlex, Ingrid Kromann has authored 23 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Infectious Diseases, 13 papers in Immunology and 10 papers in Molecular Biology. Recurrent topics in Ingrid Kromann's work include Tuberculosis Research and Epidemiology (12 papers), vaccines and immunoinformatics approaches (10 papers) and Immunodeficiency and Autoimmune Disorders (7 papers). Ingrid Kromann is often cited by papers focused on Tuberculosis Research and Epidemiology (12 papers), vaccines and immunoinformatics approaches (10 papers) and Immunodeficiency and Autoimmune Disorders (7 papers). Ingrid Kromann collaborates with scholars based in Denmark, Netherlands and United States. Ingrid Kromann's co-authors include Peter Andersen, Peter Fibiger Bang, Tom H. M. Ottenhoff, Jaap T. van Dissel, Birgit Thierry-Carstensen, Søren T. Hoff, Corine Prins, Lars Vibe Andreasen, Karen Lingnau and Morten Rühwald and has published in prestigious journals such as The Journal of Immunology, PLoS ONE and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

Ingrid Kromann

23 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ingrid Kromann Denmark	15	828	759	473	374	170	23	1.4k
Marta Sánchez‐Hernández Netherlands	7	1.1k 1.3×	373 0.5×	318 0.7×	341 0.9×	68 0.4×	9	1.6k
J. Bruce McClain United States	17	825 1.0×	1.1k 1.4×	590 1.2×	265 0.7×	100 0.6×	29	1.8k
Elisabetta Monaci Italy	13	875 1.1×	301 0.4×	437 0.9×	408 1.1×	166 1.0×	14	1.4k
H. M. Vordermeier United Kingdom	22	539 0.7×	1.2k 1.6×	1.0k 2.1×	333 0.9×	255 1.5×	36	1.6k
María E. Sarmiento Malaysia	17	372 0.4×	482 0.6×	387 0.8×	343 0.9×	162 1.0×	87	1.1k
Homayoun Shams United States	23	748 0.9×	871 1.1×	758 1.6×	298 0.8×	64 0.4×	34	1.8k
David Verhoeven United States	17	706 0.9×	387 0.5×	520 1.1×	222 0.6×	86 0.5×	34	1.4k
Georgia Deliyannis Australia	20	718 0.9×	237 0.3×	592 1.3×	326 0.9×	109 0.6×	34	1.3k
Akira Ainai Japan	25	762 0.9×	348 0.5×	772 1.6×	295 0.8×	109 0.6×	66	1.6k
Anja Weinreich Olsen Denmark	22	1.4k 1.7×	1.4k 1.8×	1.1k 2.4×	550 1.5×	596 3.5×	39	2.4k

Countries citing papers authored by Ingrid Kromann

Since Specialization

Citations

This map shows the geographic impact of Ingrid Kromann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ingrid Kromann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ingrid Kromann more than expected).

Fields of papers citing papers by Ingrid Kromann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ingrid Kromann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ingrid Kromann. The network helps show where Ingrid Kromann may publish in the future.

Co-authorship network of co-authors of Ingrid Kromann

This figure shows the co-authorship network connecting the top 25 collaborators of Ingrid Kromann. A scholar is included among the top collaborators of Ingrid Kromann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ingrid Kromann. Ingrid Kromann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Magini, Diletta, et al.. (2024). A Strategic Guide to Improve and De-Risk Vaccine Development: CEPI’s CMC Framework. PDA Journal of Pharmaceutical Science and Technology. 78(5). 613–623. 2 indexed citations

Tait, Dereck, Andreas H. Diacon, Álvaro H. Borges, et al.. (2024). Safety and Immunogenicity of the H56:IC31 Tuberculosis Vaccine Candidate in Adults Successfully Treated for Drug-Susceptible Pulmonary Tuberculosis: A Phase 1 Randomized Trial. The Journal of Infectious Diseases. 230(5). 1262–1270. 6 indexed citations

Avumegah, Michael S., Giada Mattiuzzo, Mark Page, et al.. (2023). Availability and use of Standards in vaccine development. npj Vaccines. 8(1). 95–95. 6 indexed citations

Abraham, Sonya, Helene Bæk Juel, Peter Fibiger Bang, et al.. (2019). Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial. The Lancet Infectious Diseases. 19(10). 1091–1100. 135 indexed citations

Suliman, Sara, Angelique Kany Kany Luabeya, Hennie Geldenhuys, et al.. (2018). Dose Optimization of H56:IC31 Vaccine for Tuberculosis-Endemic Populations. A Double-Blind, Placebo-controlled, Dose-Selection Trial. American Journal of Respiratory and Critical Care Medicine. 199(2). 220–231. 76 indexed citations

Hussein, Jemal, Martha Zewdie, Lawrence Yamuah, et al.. (2018). A phase I, open-label trial on the safety and immunogenicity of the adjuvanted tuberculosis subunit vaccine H1/IC31® in people living in a TB-endemic area. Trials. 19(1). 24–24. 21 indexed citations

Vesikari, Timo, Markus Maeurer, Raija Ahmed, et al.. (2017). Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials. Vaccine. 35(12). 1652–1661. 41 indexed citations

Rivera, Luis, Rasmus S. Pedersen, Lars Vibe Andreasen, et al.. (2017). Immunogenicity and safety of three aluminium hydroxide adjuvanted vaccines with reduced doses of inactivated polio vaccine (IPV-Al) compared with standard IPV in young infants in the Dominican Republic: a phase 2, non-inferiority, observer-blinded, randomised, and controlled dose investigation trial. The Lancet Infectious Diseases. 17(7). 745–753. 9 indexed citations

Tingskov, Pernille N., Bettina S. Nedergaard, Lars Vibe Andreasen, et al.. (2016). First-in-human safety and immunogenicity investigations of three adjuvanted reduced dose inactivated poliovirus vaccines (IPV-Al SSI) compared to full dose IPV Vaccine SSI when given as a booster vaccination to adolescents with a history of IPV vaccination at 3, 5, 12 months and 5 years of age. Vaccine. 35(4). 596–604. 5 indexed citations

10.

Lenz, Nicole, Tobias Schindler, Benjamin M. Kagina, et al.. (2015). Antiviral Innate Immune Activation in HIV-Infected Adults Negatively Affects H1/IC31-Induced Vaccine-Specific Memory CD4⁺T Cells. Clinical and Vaccine Immunology. 22(7). 688–696. 7 indexed citations

11.

Geldenhuys, Hennie, Helen Mearns, David J. C. Miles, et al.. (2015). The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial. Vaccine. 33(30). 3592–3599. 56 indexed citations

12.

Dissel, Jaap T. van, Simone A. Joosten, Søren T. Hoff, et al.. (2014). A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human. Vaccine. 32(52). 7098–7107. 190 indexed citations

13.

Reither, Klaus, Nicole Lenz, Khadija Said, et al.. (2014). Safety and Immunogenicity of H1/IC31®, an Adjuvanted TB Subunit Vaccine, in HIV-Infected Adults with CD4+ Lymphocyte Counts Greater than 350 cells/mm3: A Phase II, Multi-Centre, Double-Blind, Randomized, Placebo-Controlled Trial. PLoS ONE. 9(12). e114602–e114602. 49 indexed citations

14.

Román, Raúl Gómez, Kristoffer Jarlov Jensen, Sanne Jensen, et al.. (2013). Therapeutic Vaccination Using Cationic Liposome-Adjuvanted HIV Type 1 Peptides Representing HLA-Supertype-Restricted Subdominant T Cell Epitopes: Safety, Immunogenicity, and Feasibility in Guinea-Bissau. AIDS Research and Human Retroviruses. 29(11). 1504–1512. 46 indexed citations

15.

Karlsson, Ingrid, Lea Brandt, Lasse Vinner, et al.. (2012). Adjuvanted HLA-supertype restricted subdominant peptides induce new T-cell immunity during untreated HIV-1-infection. Clinical Immunology. 146(2). 120–130. 36 indexed citations

16.

Dissel, Jaap T. van, Darius Soonawala, Simone A. Joosten, et al.. (2011). Ag85B–ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection. Vaccine. 29(11). 2100–2109. 104 indexed citations

17.

Dissel, Jaap T. van, Sandra M. Arend, Corine Prins, et al.. (2010). Ag85B–ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers. Vaccine. 28(20). 3571–3581. 166 indexed citations

18.

Ottenhoff, Tom H. M., T. Mark Doherty, Jaap T. van Dissel, et al.. (2010). First in humans: A new molecularly defined vaccine shows excellent safety and strong induction of long-livedMycobacterium tuberculosis-specific Th1-cell like responses. Human Vaccines. 6(12). 1007–1015. 52 indexed citations

19.

Lewis, D. J., Zhiming Huo, Susan W. Barnett, et al.. (2009). Transient Facial Nerve Paralysis (Bell's Palsy) following Intranasal Delivery of a Genetically Detoxified Mutant of Escherichia coli Heat Labile Toxin. PLoS ONE. 4(9). e6999–e6999. 237 indexed citations

20.

Skeiky, Yasir A. W., Jes Dietrich, Todd Lasco, et al.. (2009). Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime–boost regimen. Vaccine. 28(4). 1084–1093. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact